NASDAQ OMX

hemCheck approved for trading on Nasdaq First North - Regulatory

Dela

hemCheck approved for trading on Nasdaq First North - Regulatory

This Press Release should not be released or distributed, directly or indirectly, within USA, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa, New Zealand or any other jurisdictions where distribution would be subject to legal restrictions.

Nasdaq First North has approved hemCheck Sweden AB's (publ) ('hemCheck' or the 'Company') application for listing of the Company's shares, and subscription option rights of series TO 1, for admission for trading on Nasdaq First North. The first trading day will be 15 March 2017. The ticker symbol for the Company's shares on First North is HEMC, the ticker symbol for the subscription option rights is HEMC TO 1.

hemCheck develops and commercializes a unique product concept (Helge(TM) and READY(TM)) that detects hemolysis in blood samples at the point of care. Nasdaq Stockholm AB has approved hemCheck's application for the Company's shares and subscription option rights (series TO 1) to begin trading on Nasdaq First North. The first day of trading will be March 15, 2017.

hemCheck CEO Annelie Brolinson:
"We're delighted interest in our share issue has been so great. We look forward to begin trading on 15 March. The whole team at hemCheck will continue to keep working hard to meet all our shareholders' expectations. As previously announced we will now finalize our product concept, consisting of Helge(TM) and READY(TM), for CE marking. We can then go full speed ahead with the market launch of our concept, starting in Sweden."

Background
In February hemCheck announced that the company had received over 1900 new shareholders through a new issue of units. Each unit consisted of one share and one subscription option rights of series TO 1. With subscription option rights issued free of charge the subscription price per unit amounted to SEK 6 per share. The issue volume of 28.2 million initially signed to approximately 59 MSEK, a subscription rate equivalent to approx. 209%. As the rights issue was oversubscribed, the Board decided to make full use of an over-allotted issue. The company thus initially raised approx. 30 MSEK prior to listing, and if all share issue costs and / or all outstanding subscription option rights will be used before Q1 2018, the Company will receive an additional 30 MSEK before issue costs.

The ticker symbol for the Company's shares on First North is HEMC, the ticker symbol for subscription option rights is HEMC TO 1.

Conditions for subscription option rights
Possession of a series TO 1 subscription option rights entitles the owner to subscribe for one of the new shares at a price of SEK 6 for a period from 29 January 2018, up to and including 9 February 2018.

Full details on how warrants will be used for subscription of shares in hemCheck will be made available on the Company's website,www.hemcheck.com, and Aktieinvest's website www.aktieinvest.se from 29 January 2018. Full terms and conditions for the warrants of series TO 1 will be detailed in the section Full terms and conditions for the warrants of series TO 1 in the prospectus being prepared for the new share issue, which is available on the Company website.

Advisors
Corpura AB is the financial advisor for the new share issue, and Fredersen Advokatbyrå AB is acting legal advisor. hemCheck's Certified Adviser on Nasdaq First North will be Corpura AB. Aktieinvest FK AB is acting as receiving agent in connection with the rights issue.

About hemCheck
hemCheck Sweden AB (publ) develops and commercializes a unique product concept (HELGE(TM) and READY(TM)) that detects hemolysis in blood samples at the point of care. Hemolysis, or the rupturing of red blood cells, is the most common reason for blood samples being unfit for analysis-which can lead to poorer healthcare, increased risk for patients and higher costs for clinics and society. By detecting hemolysis in blood tests directly, HELGE(TM) can contribute to improved care for patients throughout the world. hemCheck is headquartered in Karlstad, Sweden. hemCheck prepared a prospectus for the issue of new units before its resumption of trading on Nasdaq First North.

Contact
hemCheck Sweden AB (publ)
Annelie Brolinson, CEO
Tel: +46 70 288 0826
E-post: annelie.brolinson@hemcheck.com
Universitetsgatan 2
651 88 Karlstad
www.hemcheck.com

Important information
The information in this press release may not be published, reproduced or distributed in or into the United States, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa or New Zealand or any other country or other jurisdiction where such action is not permitted, or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities laws.

No interim units or units have been registered and will not be registered under the United States Securities Act of 1933 (the 'Securities Act') and may not be offered, subscribed to, sold or transferred, directly or indirectly, within the United States, except with the written approval from hemCheck and pursuant to an applicable exemption from the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United states.

This is information which hemCheck is required to disclose according to EU Market Abuse Regulation law. The information was provided by the above contact person's auspices, for publication on 13 March 2017, 1725.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hemcheck Sweden AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Virgin Pulse and RedBrick Health Joining Forces to Create World's Largest Digital Employee Wellbeing and Engagement Company21.5.2018 17:00Pressmeddelande

Merger Will Create First and Only One-Stop-Shop for Employee Health, Wellbeing and Benefits Engagement; Combined Company Will Have More Than 3,300 Customers Across 190 Countries PROVIDENCE, R.I., May 21, 2018 (GLOBE NEWSWIRE) -- Providence-based Virgin Pulse and Minneapolis-based RedBrick Health announced today that the industry pioneers will merge, creating the world's largest, most comprehensive digital health and engagement company. This powerful combination will deliver the industry's only fully integrated digital platform, with benefits navigation and live coaching to support global clients and members across the entire health, wellbeing and benefits lifecycle - from screening and assessment to activation, behavior change and the adoption of sustainable, healthy habits. "We are thrilled to join with RedBrick to set a new vision and standard for employee health, wellbeing and engagement," said David Osborne, Virgin Pulse CEO, who will serve as CEO of the combined company. "Bringing

Hotels.com App Wins 2018 MediaPost Appy Award in Travel & Tourism Category21.5.2018 16:00Pressmeddelande

Developed by EPAM, app is recognized for creativity and excellence in app design NEWTOWN, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Hotels.com® and EPAM Systems, Inc. (NYSE:EPAM) announced their triumphant win at the 2018 MediaPost Appy Awards in the Travel and Tourism category this week. The Hotels.com mobile app, developed in collaboration with EPAM Systems, Inc., a leading global provider of digital platform engineering and software development services, has been crowned the best app developed for airlines, hotels, travel search engines, destinations, cruises, travel advice or car rentals. With over 70 million downloads and a 4.5+ star rating from consumers on both iOS and Android app stores, the Hotels.com app has now been recognized by the industry leading Appy Awards, which honor creativity and excellence in app design. The app provides a simple, fast and secure way for users to plan, book and manage hotel reservations, and allows travelers to book hundreds of thousands of places to

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

Claroty Launches Channel Program and Announces New Industrial Cybersecurity Partnerships21.5.2018 15:00Pressmeddelande

Claroty Vision Program Expands Global Reach and Joint Solution Delivery with OT Leaders, Including Dimension Data/NTT Security, Optiv, and Kudelski Security NEW YORK, May 21, 2018 (GLOBE NEWSWIRE) -- Claroty, the leader in operational technology (OT) network security, today unveiled Claroty Vision, a new global channel partner program for integrated solution partners, managed service providers (MSPs), and resellers. The program is tailored to provide partners with the tools and resources they need to accelerate revenue in the fast-growing industrial cybersecurity market. The company also announced several new partnerships under the Claroty Vision banner, including the addition of Optiv and Kudelski Security. Comprised of four participation levels - Elite, Premier, Authorized, and Referral - the Claroty Vision program provides partners with a broad range of tools, benefits, and incentives such as increased margin, deal registration, an online demo environment, and co-marketing activitie

Wabtec and GE Transportation to Merge, Creating Global Leader for Rail Equipment, Services and Software21.5.2018 13:00Pressmeddelande

Strategic Combination Will Drive Shareholder Value Creation by Accelerating Innovation in Transportation and Logistics Following the transaction, Wabtec will have approximately $8 billion in revenues, a more diversified business mix, higher margins, and approximately 15 percent cash EPS accretion in year one. Both businesses are expected to benefit from the cyclical tailwinds they are experiencing as industry conditions improve. Complementary businesses and large global installed base will create additional opportunities for cross-selling, aftermarket services growth and new solutions in a rapidly evolving industry. GE Transportation is positioned for a substantial rebound, with estimated adjusted EBITDA growing from about $750 million in 2018 to between $900 million and $1 billion in 2019. Substantial annual run-rate synergies of $250 million and a net present value of approximately $1.1 billion of net tax benefit will accrue to the combined company. The transaction is valued at appro

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum